Zobrazeno 1 - 10
of 644
pro vyhledávání: '"M Spino"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Joel M. Schrock, Gavril W. Pasternak, Christina M. Spino, Stacy M. Stabler, Charles G. Longen, Felix J. Kim, Jacqueline C. Marino
Publikováno v:
Molecular pharmacology. 84(5)
The Sigma1 receptor (Sigma1) is an endoplasmic reticulum (ER) integral membrane protein that is highly expressed in a number of cancer cell lines. Small molecule compounds targeting Sigma1 (Sigma1 ligands) inhibit cancer cell proliferation and induce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc5977b166539ad92ce5970f166bc75
https://pubmed.ncbi.nlm.nih.gov/24006496
https://pubmed.ncbi.nlm.nih.gov/24006496
Autor:
Amid Khan, Eric Gnall, MaryAnn C. Wertan, Marwan Badri, Francis P. Sutter, Timothy Shapiro, Paul Coady, Christina M. Spino, Frank C. McGeehin
Publikováno v:
Journal of the American College of Cardiology. 67:112
Multiple options for the treatment of multivessel disease now exist including hybrid revascularization. Nuances in hybrid revascularization need further evaluation including timing of these procedures and optimal antiplatelet therapy. We retrospectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c47c0d4888af4dc26bf3269f2cd940ab
https://doi.org/10.1016/s0735-1097(16)30113-9
https://doi.org/10.1016/s0735-1097(16)30113-9
Publikováno v:
Biochemical and biophysical research communications. 426(2)
Treatment with sigma1 receptor (Sigma1) ligands can inhibit cell proliferation in vitro and tumor growth in vivo. However, the cellular pathways engaged in response to Sigma1 ligand treatment that contribute to these outcomes remain largely undefined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97221e023584c85ef398e5d216aa4500
https://pubmed.ncbi.nlm.nih.gov/22925888
https://pubmed.ncbi.nlm.nih.gov/22925888
Autor:
Hemami, Reyhaneh Mokhtari1, Farhangi, Mahdieh Abbasalizad2 abbasalizad_m@yahoo.com, Rouzi, Mohammad Dehghan3, Abdi, Fatemeh2
Publikováno v:
BMC Endocrine Disorders. 8/5/2024, Vol. 24 Issue 1, p1-16. 16p.
Autor:
Lv, Qingbo1 (AUTHOR), Lin, Jun1,2 (AUTHOR), Huang, He1 (AUTHOR), Ma, Boxuan1 (AUTHOR), Li, Wujiao1 (AUTHOR), Chen, Jiawen1 (AUTHOR), Wang, Meihui1 (AUTHOR), Wang, Xiaoyu3 (AUTHOR) xy_wang@zju.edu.cn, Fu, Guosheng1 (AUTHOR) fugs@zju.edu.cn, Xiao, Yun1 (AUTHOR) xiaoyun@zju.edu.cn
Publikováno v:
Advanced Science. 7/3/2024, Vol. 11 Issue 25, p1-14. 14p.
Publikováno v:
Medical Hypotheses. 51:489-491
Several clinical studies demonstrate reduced serum concentrations of renally excreted drugs in patients with cystic fibrosis (CF). To explain this phenomenon, we propose a model supporting increased proximal tubular secretion of certain drugs in indi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63a01c1627223164f9dbe4f8fa2a5ee0
https://doi.org/10.1016/s0306-9877(98)90070-6
https://doi.org/10.1016/s0306-9877(98)90070-6
Publikováno v:
Mutagenesis. 18(5)
Measurements of chromosomal aberrations were made in 10 thalassaemia major patients treated long-term with deferiprone (at least 5 years) and compared with an equal number of patients matched for age, sex and iron overload, treated long-term with def
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a95d57d3e9eaf1685beff18052735bb2
https://pubmed.ncbi.nlm.nih.gov/12960415
https://pubmed.ncbi.nlm.nih.gov/12960415
Publikováno v:
Pharmaceutical Research; Feb2006, Vol. 23 Issue 2, p280-290, 11p